Aloxi is a brand name of palonosetron, approved by the FDA in the following formulation(s):
ALOXI (palonosetron hydrochloride - injectable; intravenous)
Manufacturer: HELSINN HLTHCARE
Approval date: July 25, 2003
Strength(s): EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) [RLD]
Manufacturer: HELSINN HLTHCARE
Approval date: February 29, 2008
Strength(s): EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) [RLD]
Has a generic version of Aloxi been approved?
No. There is currently no therapeutically equivalent version of Aloxi available.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aloxi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: About generic drugs.
Related Patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
Tricyclic 5-HT.sub.3 receptor antagonists
Patent 5,202,333
Issued: April 13, 1993
Inventor(s): Berger; Jacob & Clark; Robin D. & Eglen; Richard M. & Smith; William L. & Weinhardt; Klaus K.
Assignee(s): Syntex (U.S.A.) Inc.
The present invention is directed to 5-HT.sub.3 receptor antagonist compounds of formula I: ##STR1## in which the dashed line denotes an optional double bond; n is 1, 2 or 3; p is 0, 1, 2 or 3; q is 0, 1 or 2; each R.sup.1 is independently selected from halogen, hydroxy, lower alkoxy, lower alkyl, nitro, amino, amino carbonyl, (lower alkyl)amino, di(lower alkyl)amino, and (lower alkanoyl)amino; each R.sup.2 is lower alkyl; and R.sup.3 is a group selected from Formulae (a), (b), (c) and (d): ##STR2## in which u is 0 or 1; z is 1, 2 or 3; and R.sup.4 is C.sub.1-7 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkyl-C.sub.1-2 alkyl, or a group (CH.sub.2).sub.t R.sup.5 where t is 1 or 2 and R.sup.5 is thienyl, pyrrolyl, or furyl, each optionally further substituted by one or two substituents selected from C.sub.1-6 alkyl, C.sub.1-6 alkoxy, trifluoromethyl or halogen, or is phenyl optionally substituted by one or two substituents selected from C.sub.1-4 alkoxy, trifluoromethyl, halogen, nitro, carboxy, esterified carboxy, and C.sub.1-4 alkyl optionally substituted by hydroxy, C.sub.1-4 alkoxy, carboxy, esterified carboxy or in vivo hydrolyzable acyloxy; and the pharmaceutically acceptable salts, individual isomers, mixtures of isomers, processes for preparation, compositions, and methods of use thereof.Patent expiration dates:
- April 13, 2015✓✓✓
- April 13, 2015✓✓✓
- April 13, 2015
Liquid pharmaceutical formulations of palonosetron
Patent 7,947,724
Issued: May 24, 2011
Inventor(s): Calderari; Giorgio & Bonadeo; Daniele & Cannella; Roberta & Braglia; Enrico & Braglia; Riccardo & Miksztal; Andrew & Malefyt; Thomas & Lee; Kathleen M.
Assignee(s): Helsinn Healthcare S.A.
Roche Palo Alto LLC
The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.Patent expiration dates:
- January 30, 2024✓
- January 30, 2024
Liquid pharmaceutical formulations of palonosetron
Patent 7,947,725
Issued: May 24, 2011
Inventor(s): Calderari; Giorgio & Bonadeo; Daniele & Cannella; Roberta & Braglia; Enrico & Braglia; Riccardo & Miksztal; Andrew & Malefyt; Thomas & Lee; Kathleen M.
Assignee(s): Helsinn Healthcare S.A.
Roche Palo Alto LLC
The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.Patent expiration dates:
- January 30, 2024✓
- January 30, 2024
Liquid pharmaceutical formulations of palonosetron
Patent 7,960,424
Issued: June 14, 2011
Inventor(s): Calderari; Giorgio & Bonadeo; Daniele & Cannella; Roberta & Braglia; Enrico & Braglia; Riccardo & Miksztal; Andrew & Malefyt; Thomas & Lee; Kathleen M.
Assignee(s): Helsinn Healthcare S.A.
Roche Palo Alto LLC
The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.Patent expiration dates:
- January 30, 2024✓
- January 30, 2024
Related Exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
- Exclusivity expiration dates:
- March 1, 2011 - PREVENTION OF POST OPERATIVE NAUSEA AND VOMITING FOR UP TO 24 HOURS FOLLOWING SURGERY
- March 1, 2011 - NEW STRENGTH
- August 22, 2011 - NEW DOSAGE FORM
See also...
- Aloxi Consumer Information (Drugs.com)
- Aloxi Consumer Information (Wolters Kluwer)
- Aloxi Capsules Consumer Information (Wolters Kluwer)
- Aloxi Consumer Information (Cerner Multum)
- Aloxi Advanced Consumer Information (Micromedex)
- Aloxi AHFS DI Monographs (ASHP)
- Palonosetron Consumer Information (Wolters Kluwer)
- Palonosetron Capsules Consumer Information (Wolters Kluwer)
- Palonosetron Consumer Information (Cerner Multum)
- Palonosetron Advanced Consumer Information (Micromedex)
- Palonosetron Intravenous Advanced Consumer Information (Micromedex)
- Palonosetron Hydrochloride AHFS DI Monographs (ASHP)
No comments:
Post a Comment